Replies to post #137778 on Biotech Values

[ciotera]

RE: HCV LoT

..it could be harder for drugmakers to convince third-party payers of the fairness of a high cumulative treatment price if the duration were unduly short

I think this is a stretch.. I don't think there is such a thing as "unduly short" regimen that cures a patient of their disease. The shorter the better - if you could cure it in one day and charged costs comparable to 12 month therapy (or more), I think payers would still understand the benefit. It would be unwise not to try to minimize the LoT. Any hypothetical "discomfort" justifying high per day therapy cost to payers is surely offset by the benefit of better persistency and compliance on a shorter regimen.